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Abstract 
Patients undergoing percutaneous coronary intervention (PCI) are treated with dual antiplatelet therapy 
to reduce the risk of subsequent myocardial infarction and stent thrombosis. Approximately 5-10% of 
patients undergoing PCI also have atrial fibrillation (AF). Patients with AF have an additional 
requirement for anticoagulation, as dual antiplatelet therapy alone is insufficient to adequately reduce 
the risk of stroke in patients with AF. However, it is now well-established that combining anticoagulants 
with dual antiplatelet therapy also causes a significant increase in the risk of bleeding. Hence, there is 
great interest in discovering the optimal blend of antiplatelet therapy and oral anticoagulation in this 
situation, aiming to reduce the risk of stent thrombosis, recurrent MI, and stroke, whilst also minimizing 
the risk of bleeding. Recent studies have experimented with combining oral anticoagulation with a single 
antiplatelet agent, rather than combining oral anticoagulation with dual antiplatelet therapy. These 
studies show that this reduces the risk of bleeding, but are underpowered to determine whether this still 
provides as much cardiovascular benefit. 
This review summarizes the currently available evidence on this topic and highlights the key questions 
that remain to be answered including ongoing clinical trials in the field. 
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Introduction 
Over the last decade, revascularization by percutaneous coronary intervention (PCI) has become the 
standard of care for patients with acute coronary syndrome (ACS).1,2 Dual antiplatelet therapy has a 
major role in reducing the risk of secondary events in patients with ACS and in the prevention of stent 
thrombosis for patients undergoing PCI.3 Approximately 5-10% of patients undergoing PCI also have 
atrial fibrillation (AF).4 The vast majority of these patients will have a clear indication for oral 
anticoagulation to prevent ischemic strokes in addition to their requirement for antiplatelet therapy. In 
recent years, the number of available antiplatelet agents and anticoagulants has greatly increased (Table 
1). This presents many different possible combinations of treatment, each of varying antithrombotic 
potency. In this review, we summarise the evidence for currently recommended treatment strategies for 
the management of these complex patients. 
Antiplatelet Therapy in Patients with Acute Coronary Syndromes or 
Undergoing Percutaneous Coronary Intervention 
Most ACS are caused by thrombosis within the coronary arteries at high levels of shear stress, which is 
largely mediated by platelets. Aspirin inhibits an important amplificatory pathway in platelets, mediated 
by inhibition of cyclooxygenase (COX)-1 and reduced synthesis of thromboxane A2 (Figure 1), which 
is well-known to reduce the risk of cardiovascular death in patients with ACS.5 Platelet P2Y12 receptors 
have a central role in amplifying the response of platelets to a wide range of different agonists (Figure 
1).6 Each generation of platelet P2Y12 inhibitor has incrementally reduced the risk of adverse 
cardiovascular events, particularly stent thrombosis, in patients with ACS. In patients with ACS or 
undergoing PCI, the addition of clopidogrel to aspirin (dual antiplatelet therapy) reduces the relative 
risk of major adverse cardiovascular events by approximately 20% compared to aspirin alone.3 In 
patients with ACS undergoing PCI, more potent oral P2Y12 antagonists, such as prasugrel7 and 
ticagrelor,8 have been shown to further reduce the relative risk of adverse cardiovascular events by 
approximately 15-20% compared to clopidogrel, but at the expense of an increased bleeding risk (Figure 
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2). Increased potency of P2Y12 inhibitors has led to less of a need for GPIIb/IIIa inhibitors, which further 
increase the risk of bleeding and are therefore reserved for “bailout” therapy.7 Guidelines now 
recommend the use of prasugrel and ticagrelor in preference to clopidogrel in patients with ACS 
undergoing PCI, due to the cardiovascular benefit of these newer agents.1,2 
Oral Anticoagulation in Atrial Fibrillation 
AF is independently associated with an increase in mortality and morbidity and its incidence has steadily 
increased over the past 20 years.9 The pathophysiology of stroke in AF is complex and multifactorial, 
reflecting stasis of blood in the atria, endothelial expression of prothrombotic factors, and a systemic 
proinflammatory, prothrombic state.10 Although there is still incomplete understanding of these 
processes, oral anticoagulation prevents the majority of strokes in patients with AF,10 while aspirin or 
the combination of aspirin and clopidogrel do not substantially contribute to stroke prevention in AF 
patients.10, 11 
European Society of Cardiology (ESC) guidelines recommend the use of the CHA2DS2-VASc score for 
stratifying stroke risk.10 Patients with a score of 1 for men, or 2 for women, should be considered for 
oral anticoagulation, while those with 2 or more stroke risk factors (a score of 3 or more for women), 
have a clear indication for long-term oral anticoagulation. The complexities of treatment with vitamin 
K antagonists (VKA), such as warfarin, led to the development of non-vitamin K oral anticoagulants 
(NOACs). Currently, the direct thrombin inhibitor dabigatran and the Factor Xa inhibitors apixaban, 
edoxaban, and rivaroxaban are licenced for stroke prevention in AF.  NOACs are as effective as warfarin 
for stroke prevention in AF while reducing stroke, intracranial haemorrhage (ca 50%) and mortality (ca 
10%) compared with warfarin in patients with non-valvular AF.13,14 Notably, the lower risk of bleeding 
related to the use of NOACs compared to VKAs is also observed in AF patients who are treated with 
either single or dual antiplatelet therapy.12 
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Evaluation of Triple Therapy in Patients Undergoing Percutaneous 
Coronary Intervention without Atrial Fibrillation 
Unfortunately, antiplatelet therapy does not adequately prevent stroke in patients with AF11 and 
anticoagulants do not seem to adequately prevent stent thrombosis in patients undergoing PCI with first 
generation bare-metal stents (although it is unknown whether this is still the case in the current era of 
newer, drug-eluting stents with thinner struts).13 Therefore, when patients with AF undergo PCI, there 
is a need to combine antiplatelet therapy with oral anticoagulants (triple therapy) to prevent stent 
thrombosis, recurrent MI and stroke. The efficacy of different combinations of antithrombotic therapy 
in this situation is a topic for debate with conflicting evidence and a need for more solid evidence from 
controlled trials. 
Recent randomised controlled trials in patients without AF provide insight into the impact of triple 
therapy on cardiovascular and bleeding endpoints in patients with ACS (Figure 3). In 2013, a meta-
analysis evaluated the use of NOACs in addition to dual antiplatelet therapy in patients with ACS on 
the basis of seven randomised phase 2 and phase 3 trials.12 This analysis showed that the addition of a 
NOAC to dual antiplatelet therapy results in only a modest reduction in cardiovascular events compared 
to placebo (HR 0.87; 95% CI 0.80-0.95) with a substantial increase in bleeding (HR 2.34; 95% CI 2.06 
– 2.66). The APPRAISE-2 and ATLAS-2 studies, which compared standard-dose apixaban and very 
low-dose rivaroxaban respectively to placebo in ACS patients receiving antiplatelet therapy, were the 
only phase III studies included in the meta-analysis. APPRAISE-2 enrolled 7,392 ACS patients.14 Most 
patients were on dual antiplatelet therapy, usually aspirin and clopidogrel. The patients were randomised 
to apixaban in the dose currently approved for stroke prevention in AF (Table 1) or placebo. The trial 
was stopped early after recruitment of 7,392 patients because the addition of apixaban to antiplatelet 
therapy increased TIMI major bleeding compared to placebo with no significant reduction in ischaemic 
events. Further post-hoc analysis concluded apixaban increased bleeding both in patients treated with 
single or dual antiplatelet therapy.15 The ATLAS ACS 2-TIMI-51 study randomised 15,526 ACS 
patients to twice-daily doses of 2.5 mg rivaroxaban, 5 mg rivaroxaban or placebo in addition to 
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antiplatelet therapy, mostly consisting of aspirin and clopidogrel. Both rivaroxaban doses were greatly 
lower than the doses approved for stroke prevention in AF (Table 1).16 The twice-daily 2.5 mg dose of 
rivaroxaban significantly reduced the risk of adverse cardiovascular events compared to placebo (8.9% 
vs. 10.7%; HR 0.84; 95% CI 0.74 – 0.96; P=0.008), but also significantly increased the risk of TIMI 
major bleeding (2.1% vs. 0.6%; HR 3.96; 95% CI 2.46 – 6.38; P<0.001). 
Evaluation of Triple Therapy in Patients with Atrial Fibrillation Undergoing 
Percutaneous Coronary Intervention 
The WOEST study randomised 573 patients undergoing PCI with an indication for oral anticoagulation 
(approximately two thirds had AF) to anticoagulation plus clopidogrel (dual therapy) or to 
anticoagulation plus clopidogrel plus aspirin (triple therapy) for 1 year.17 Patients on clopidogrel plus 
anticoagulation had significantly fewer bleeding episodes (19.4% vs. 44.4%; HR 0.36; 95% CI 0.26 – 
0.50; P < 0.001) with no significant difference in the incidence of MI or stent thrombosis compared to 
patients on triple therapy. A meta-analysis of smaller, randomised studies prior to the WOEST study 
also showed that triple therapy was associated with an approximately 2-fold increase risk of bleeding 
compared to anticoagulation combined with a single antiplatelet in patients with AF undergoing PCI.18 
However this meta-analysis also suggested that the risk of major adverse cardiovascular events may be 
approximately 40% higher in patients treated with dual therapy compared to triple therapy.18 In contrast, 
a large Danish registry of over 12,000 patients showed that dual therapy with clopidogrel and an oral 
anticoagulant was associated with a non-significant reduction in both bleeding and adverse 
cardiovascular events compared to triple therapy (aspirin, clopidogrel and oral anticoagulant), although 
these results must be interpreted with caution due to the inherent selection bias of observational studies.19 
Based on this data, the ESC currently recommends to consider the early omission of aspirin as soon as 
one month after the acute event in ACS patients with AF at high risk of bleeding and low risk of recurrent 
thrombotic events.10 Conversely, some patients may require prolonged triple therapy of 12 months or 
longer if the risk of stent thrombosis is very high. In addition to clinical risk factors (Figure 2), the use 
of longer stents with smaller diameters, bioabsorbable stents, or complex PCI may indicate a need for 
 7 
prolonged triple therapy (Figure 2). 
The recent PIONEER AF-PCI study compared the effect of 3 different antithrombotic regimens on 
bleeding in 2,124 patients with AF undergoing PCI.20 The primary outcome of the trial was bleeding, 
while the study was not powered to detect differences in ischaemic (stroke) events. Dual therapy with 
low-dose rivaroxaban (15 mg once daily, which is lower than the 20mg dose approved for stroke 
prevention in AF patients with normal renal function) and a single P2Y12 inhibitor (for 1 year) 
significantly reduced the incidence of bleeding compared to standard triple therapy, consisting of aspirin 
(for 12 months), a P2Y12 inhibitor (for 1, 6 or 12 months) and warfarin indefinitely at an international 
normalised ratio (INR) of 2-3 (16.8% vs. 26.7%; HR 0.59; 95% CI 0.47 – 0.76; P < 0.001). There was 
no significant difference in major adverse cardiovascular events between these 2 groups (41 [6.5%] vs. 
36 [6.0%]; HR 1.08; 95% CI 0.69 – 1.68; P = 0.75). Clopidogrel was the the most commonly used P2Y12 
inhibitor (used in > 90% of patients, with slightly greater usage in the triple therapy group). As only a 
small number of patients received the more potent P2Y12 inhibitors, prasugrel or ticagrelor, it was not 
possible to determine whether the choice of P2Y12 inhibitor influenced the main efficacy results of the 
study. 
The PIONEER AF-PCI study also investigated whether a triple therapy strategy that includes a very 
low-dose of rivaroxaban (2.5 mg twice-daily – similar to the very low dose regimen in ATLAS-2) in 
combination with aspirin plus a P2Y12 inhibitor causes less bleeding than a standard triple therapy 
strategy including warfarin plus aspirin plus a P2Y12 inhibitor. Very low-dose rivaroxaban triple therapy 
significantly reduced the incidence of the composite bleeding endpoint compared to the standard triple 
therapy strategy (18.0% vs 26.7%; HR 0.63; 95% CI 0.5 – 0.8; P < 0.001) with no significant difference 
in major adverse cardiovascular events (5.6% vs. 6.0%; HR 0.93 [95% CI 0.59 – 1.43]; P = 0.76). 
The PIONEER AF-PCI study was too small to evaluate whether such a combination therapy would 
provide sufficient stroke prevention for AF patients undergoing PCI. Hence, there was no significant 
difference in the incidence of stroke between the groups (10 vs. 7; 1.5% vs. 1.2%; HR 1.36; 95% CI 
0.52-3.58; P=0.53). Of note, a limitation of this study is that none of the treatment arms included a 
dosing regimen of rivaroxban that has been approved for stroke prophylaxis in patients with AF. 
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Although there were no significant differences in the incidence of MI or stent thrombosis in the triple 
therapy and non-triple therapy groups in PIONEERS and WOEST, these studies were not powered to 
investigate cardiovascular endpoints. The confidence intervals do not rule out a possible increase in risk 
of myocardial infarction and stent thrombosis of up to approximately 40-70% with even greater 
uncertainty regarding the risk of stroke. It is therefore not possible to determine whether or not these 
treatment strategies are non-inferior to triple therapy for the prevention of stroke, myocardial infarction 
or stent thrombosis (Figure 3).  
More Potent P2Y12 Inhibitors in Patients with Atrial Fibrillation Undergoing 
Percutaneous Coronary Intervention 
Antiplatelet therapy in the aforementioned studies mainly consisted of aspirin and clopidogrel in 
combination with VKAs. The evidence for the use of more potent P2Y12 inhibitors in triple therapy or 
as a single antiplatelet agent in combination with an OAC derives almost entirely from observational 
studies. Of note these mainly reviewed VKAs at an INR of 2-3 with little evidence on combining the 
NOACs as dual therapy with the more potent P2Y12 inhibitors.  An evaluation of bleeding in 11,756 
patients after PCI showed that triple therapy with prasugrel, aspirin, and warfarin (91 patients) versus 
clopidogrel, aspirin, and warfarin (526 patients) was associated with a higher number of patient-reported 
bleeding events but not an increase in bleeding requiring hospitalisation.21 Similar findings of increased 
bleeding with triple therapy including prasugrel, compared to triple therapy including clopidogrel were 
also demonstrated in a small observational study that included 21 patients receiving prasugrel and 
VKAs.22 Another recent study investigated cardiovascular and bleeding outcomes in patients treated 
with triple therapy regimens (approximately 50% receiving VKAs and 50% NOACs) that included 
either clopidogrel (n = 205) or one of the more potent P2Y12 antagonists; prasugrel or ticagrelor (n = 
72).23 In this study, the incidence of adverse cardiovascular events and bleeding was not significantly 
different in patients treated with triple therapy including clopidogrel vs. triple therapy including a more 
potent P2Y12 antagonist. Braun et al. studied 109 patients treated with dual therapy with warfarin and 
ticagrelor, compared to 159 historical controls receiving aspirin, clopidogrel and warfarin (triple 
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therapy).24 The incidence of major bleeding and a composite of all thrombotic events were similar 
between the groups. In alignment with this finding, in 2 recent large randomised controlled trials, 
ticagrelor does not appear to cause significantly more bleeding than either aspirin or clopidogrel in the 
context of its use as a single antiplatelet agent.25,26  
Alleviating Bleeding Risk and Future Studies 
Bleeding risk is predominantly determined by clinical risk factors (Figure 2), but it has also been shown 
that certain genetic polymorphisms increase the risk of bleeding, mostly by influencing the metabolism 
of clopidogrel27 and warfarin 28. Proton pump inhibitors (PPIs) are effective at reducing the risk of 
gastrointestinal bleeding in patients treated with antithrombotic therapy29, but they also increase the risk 
of other serious medical conditions such as pneumonia. PPI may be useful in patients at risk of gastric 
ulcers receiving triple therapy. As there is some evidence to suggest that omeprazole may interfere with 
the metabolism of clopidogrel, treatment with lansoprazole or pantoprazole is preferable in clopidogrel-
treated patients.1,29 
The ISAR-TRIPLE randomised 614 AF patients with ACS to receive either 6 weeks or 6 months of 
clopidogrel with concomitant aspirin and OAC.30 They found no statistical difference between the 
groups (p=0.63) of a composite end point of death, MI, stent thrombosis, stroke and TIMI major 
bleeding. The authors concluded that a shorter duration of clopidogrel in triple therapy was not superior 
in regards to clinical outcomes and the optimal duration of triple therapy is therefore still not known. 
Further studies, including REDUAL-PCI (clinicaltrials.gov NCT02164864), AUGUSTUS 
(clinicaltrials.gov NCT02415400) and ENTRUST AF-PCI (clinicaltrials.gov NCT02866175) are 
comparing dual therapy with a NOAC and P2Y12 inhibitor compared to triple therapy with aspirin, a 
P2Y12 inhibitor and warfarin in patients with AF undergoing PCI. These studies will help to answer 
many unanswered questions in this group of patients. The REDUAL-PCI and AUGUSTUS studies will 
provide evidence as to whether or not dual therapy with dabigatran and apixaban respectively, at their 
normal stroke prophylaxis doses, offer benefit compared to triple therapy that includes a VKA. 
Furthermore, AUGUSTUS will provide insight into whether dual therapy that includes apixaban is 
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preferable to dual therapy that includes a VKA. In addition, the factorial design of AUGUSTUS will 
simultaneously help to determine whether it is of benefit to withhold aspirin in patients that are treated 
with a P2Y12 inhibitor and apixaban. 
The results of these studies, in combination with WOEST and PIONEER-AF-PCI, and eventually meta-
analyses using individual patient data sets from further studies, will help to establish whether dual 
therapy strategies are non-inferior for preventing stent thrombosis and recurrent MI compared to triple 
therapy strategies. Many, but not all, of the pathways inhibited by aspirin are also inhibited by potent 
P2Y12 inhibitors.31 It still remains to be determined whether aspirin is needed to prevent adverse 
cardiovascular events in patients with ACS if they are also treated with a P2Y12 inhibitor and 
anticoagulant. We will have to indirectly deduce what the effects of dual therapy with a potent P2Y12 
inhibitor and VKAs are. The GLOBAL LEADERS study (clinicaltrials.gov NCT01813435), 
COMPASS study (clinicaltrials.gov NCT01813435), TWILIGHT study (NCT02270242) and GEMINI 
study (clinicaltrials.gov NCT02293395) will help to clarify whether aspirin is still necessary in patients 
with ACS or undergoing PCI who are treated with potent P2Y12 inhibitors. 
Recommendations 
Management of antithrombotic therapy for patients with AF undergoing PCI is discussed in detail in the 
most recent 2016 ESC AF guidelines,10 as well as the 2015 non-ST-elevation ACS guidelines1 and ST-
elevation myocardial infarction guidelines.2 These guidelines recommend initial triple therapy 
consisting of an anticoagulant, aspirin, and clopidogrel for a relatively short duration. Although there is 
very little randomized evidence to guide the decision, the duration of triple therapy (between 1 and 6 
months, and in some patients, up to 12 months) should be chosen  by balancing the risk of bleeding and 
recurrent ACS (Figure 2). Following this initial period of triple therapy, dual therapy with an oral 
anticoagulant and either aspirin or clopidogrel should be continued for the remainder of the 12-month 
period. After this, the patient should be switched to oral anticoagulant monotherapy. If the patient has 
non-valvular AF then the anticoagulant can be either a VKA or a NOAC. As the PIONEER AF-PCI 
study was not powered to investigate efficacy endpoints, further randomized studies and meta-analyses 
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will be required before these recommendations can be modified. 
Conclusion 
As demonstrated there is a balance to be struck between safety and efficacy when combining antiplatelet 
drugs with anticoagulants. Although we now have more evidence to guide these decisions, there are still 
many ongoing questions regarding whether to use dual or triple therapy, which antiplatelet medications 
and anticoagulants should be used, and how long they should be given for. 
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Figures 
Figure 1. Mechanisms of action of antithrombotic therapy for the prevention of myocardial infarction 
and stroke. 
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Figure 2. Balancing risk factors for bleeding, stroke, MI and stent thrombosis. The individual circles 
represent approximate degree of risk for MI and stent thrombosis (blue), stroke (green) and bleeding 
(red). The circles with dotted lines illustrate factors where it is unknown whether the risk factor is a 
risk factor for bleeding and/or stroke. 
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Figure 3. The impact of different antithrombotic strategies on the risk of recurrent MI and stent 
thrombosis, risk of stroke and risk of bleeding. This figure is intended to be illustrative only and is 
based on the studies referenced in the text. 
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Tables 
Table 1. Approved doses of antithrombotic therapy 
Drug Type Name Usual treatment dose 
Oral antiplatelet therapy Clopidogrel 300-600 mg loading dose then 75 mg once 
daily (od) maintenance dose 
 Prasugrel 60 mg loading dose then 10 mg od 
maintenance dose 
 Ticagrelor 180 mg loading dose then 90 mg twice daily 
(bd) maintenance dose for 1 year after ACS 
60 mg bd maintenance dose for the period 1-
3 years after ACS 
Intravenous antiplatelet 
therapy 
Abciximab 250 mcg/kg over 1 minute then infusion of 
250 nanogram/kg/min before PCI and up to 
12 hrs afterwards 
 Eptifibitide 180 mcg/kg, then 2 mcg/kg/min for up to 96 
hours 
 Tirofiban 25 mcg/kg over 3 minutes then infusion of 
150 nanograms/kg/min for 48hrs maximum 
 Cangrelor 30 mcg/kg bolus then infusion of 4 
mcg/kg/min before PCI up to 4 hrs afterwards 
Vitamin K antagonists Warfarin 
Acenocoumarol 
Phenprocoumon 
Fluindione 
Dose adjusted according to INR 
Non-Vitamin K Oral 
Anticoagulants (NOACs) 
used for non-valvular AF 
Apixaban 5 mg bd 
2.5 mg bd if > 80 yrs old and <60 kg  
 Dabigatran 150 mg bd 
110 mg bd may be considered in patients over 
80 yrs old, or with moderate renal impairment 
or at increased risk of bleeding (EMC 
approved, but not FDA approved) 
 Edoxaban 60 mg od or 30 mg od if <60 kg 
 Rivaroxaban 20 mg od 
15 mg od (if CrCl 15-49) 
(2.5 mg bd for ACS) 
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